Press Release

QT Ultrasound Delivers the First 3D Printing of Human Breast Microanatomy In Vivo

February 28, 2019

QT Ultrasound Delivers the First 3D Printing of Human Breast Microanatomy In Vivo

3D Transmission Ultrasound Technology Advances How We Look at Breast Health


Novato, CA – February 28, 2019 – QT Ultrasound, the developer of the only FDA-cleared transmission ultrasound breast imaging technology, has now created the first 3D printing of the breast duct system in a living woman, using its technology.

Transmission ultrasound can image microanatomy in living humans and can isolate human tissue types using speed of sound. QT Ultrasound’s first application of their technology is breast imaging and the QTscan™, was cleared for marketing by the FDA in 2017. Unlike traditional breast imaging, the QTscan has no radiation, no compression, and no injections, which makes it a welcome addition to the arsenal of breast health modalities. The technology produces high-fidelity detailed scans, providing clarity even for women with dense breasts.

Beyond the accomplishments of this new imaging modality the company has now demonstrated that the technology has the ability to produce 3D printed images of a person’s breast tissue-specific microanatomy. This is the first example of 3D printing of human breast tissue-specific microanatomy using any medical imaging modality and has the potential to be a new diagnostic tool, and a new way for physicians to visualize human health and disease.

“We are on a mission to change the paradigm of breast imaging.” Says QT Ultrasound’s CEO, Dr. John Klock. “Transmission ultrasound provides high definition imaging of breast tissue, and we’re excited to show why true 3D data acquisition and image reconstruction matters.  The benefits of being able to see breast tissue information in a true 3D volume, and then segment and isolate the tissue types, include new opportunities to examine the ductal network of the female breast, in ways we never could before.”

In 2018, the Food and Drug Administration (FDA) granted  QT Ultrasound Breakthrough Device designation for its QT Scanner, potentially offering new opportunities for earlier and more frequent screening for young women at high risk for breast cancer who have no available FDA-cleared screening options.

About QT Ultrasound

QT Ultrasound® is a privately held company engaged in the research, development, and commercialization of an innovative automated breast imaging system producing high-resolution transmission ultrasound images. The company has received FDA 510(K)clearance for its QTscan™, and the National Institutes of Health (NIH) awarded over $15 million in funding to continue QT Ultrasound research.  The company’s clinical trials have been conducted at prestigious institutions in the US and Europe and include ongoing trials at the Marin Breast Health Trial Center in Novato, California. QTscans are now available commercially through the breast imaging centers of QTbreasthealth.

The QT Ultrasound Breast Scanner is indicated for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient’s breast. The device is not intended to be used as a replacement for screening mammography.